JHL1101 is currently undergoing clinical trials in the EU and is being developed for many indications including non-Hodgkin's lymphoma, chronic lymphocytic leukemia, follicular lymphoma, diffuse large B cell lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiites, and microscopic polyangiites.
JHL is an innovator in biopharmaceuticals that utilizes breakthrough engineering and process technologies to provide high quality, affordable biosimilar medicines.
Founded in 2012 by a group of industry veterans with deep experience in biologics development and operations, the mission of JHL Biotech is to provide the world with affordable medicines of exceptional quality.
With a manufacturing facility in Wuhan, China, the company is focused on research and development of new protein-based therapies and proprietary biosimilars.
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Ono partners with Shattuck Labs for bifunctional fusion proteins
Artax Biopharma doses first subject in AX-158 Phase 2a psoriasis trial
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
BioSenic expands patent coverage for ATO therapeutic platform
Celltrion USA submits CT-P47 Biologics License Application to FDA
NS Pharma's NS-229 receives European Commission orphan drug designation
Kyverna Therapeutics' KYV-101 granted US FDA fast track designation
InnoCare Pharma receives U.S. FDA clearance for ICP-248 clinical trial
Biosenic finalises agreement with Phebra for oral arsenic troxide development
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Allorion Therapeutics signs exclusive option and global license agreement with AstraZeneca